Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA-Deficient Cancer Research

Executive Summary: Olaparib (AZD2281, Ku-0059436) is a potent and selective inhibitor of poly(ADP-ribose) polymerase-1 and -2 (PARP-1/2), enzymes central to DNA repair mechanisms (Borchert et al. 2019). It exhibits nanomolar IC₅₀ values against PARP1 (5 nM) and PARP2 (1 nM) under standard in vitro conditions. Olaparib demonstrates selective cytotoxicity in BRCA- and homologous recombination-deficient models, increasing apoptosis and senescence in BAP1-mutated tumor cells. The compound is utilized for DNA damage response assays, tumor radiosensitization studies, and targeted therapy research in BRCA-associated cancers, and is available from APExBIO as SKU A4154 (product page).

Biological Rationale

Poly(ADP-ribose) polymerases (PARPs) are enzymes involved in the detection and repair of DNA single-strand breaks (SSBs). When PARP1 or PARP2 activity is inhibited, SSBs accumulate, progressing into double-strand breaks (DSBs) during DNA replication. Cells with homologous recombination deficiency (HRD), such as those with BRCA1/2 or BAP1 mutations, are unable to repair DSBs effectively, leading to cell death. This synthetic lethality principle underpins the use of PARP inhibitors like Olaparib in cancer research (Borchert et al. 2019). 'BRCAness' refers to phenotypes mimicking BRCA loss, often seen in malignant pleural mesothelioma (MPM) and other cancers, conferring heightened sensitivity to PARP inhibition.

Mechanism of Action of Olaparib (AZD2281, Ku-0059436)

Olaparib is a competitive inhibitor of the NAD⁺-binding site on PARP1 and PARP2, with IC₅₀ values of 5 nM and 1 nM, respectively, in cell-free enzyme assays at 25°C and pH 7.5 (APExBIO). Upon binding, Olaparib prevents PARylation of DNA repair proteins, halting base excision repair (BER) and trapping PARP on chromatin. In HR-deficient cells, unrepaired DNA damage triggers apoptosis via caspase signaling. In tumor models, Olaparib increases radiosensitivity by amplifying DNA damage and modulating tumor perfusion (Borchert et al. 2019).

Evidence & Benchmarks

• Olaparib induces apoptosis and senescence in BAP1-mutated, HR-deficient mesothelioma cells, with significant effects observed at 10 μM for 1 hour in vitro (Borchert et al. 2019).
• Gene expression profiling identifies 10% of MPM patient samples with a BRCAness phenotype, correlating to increased Olaparib susceptibility (Borchert et al. 2019).
• Combined Olaparib and cisplatin therapy potentiates cytotoxicity in BAP1-mutated cell lines, supporting synergistic regimens (Borchert et al. 2019).
• Olaparib enhances radiosensitivity in NSCLC xenografts, increasing DNA damage markers and improving tumor perfusion (internal article).
• ATM kinase deficiency further sensitizes cells to Olaparib, indicating pathway cross-talk (APExBIO).

Applications, Limits & Misconceptions

Olaparib is widely employed in research protocols investigating PARP-mediated DNA repair, homologous recombination deficiency, and BRCA-associated cancer therapy. It is instrumental in DNA damage response assays, tumor radiosensitization studies, and in vivo models for translational oncology (related article, which provides troubleshooting and workflow details; this article extends the clinical and mechanistic context).

Internal resources such as this in-depth review focus on benchmarking Olaparib in DNA damage response; herein, we emphasize cross-validated clinical datasets and provide updated mechanistic insights.

For advanced mechanistic exploration, this article provides additional context on radiosensitization; our coverage includes quantitative in vivo benchmarks and the impact of combinatorial treatments.

Common Pitfalls or Misconceptions

• Olaparib is not cytotoxic in cells with intact homologous recombination pathways; efficacy depends on HR deficiency (Borchert et al. 2019).
• Long-term storage of Olaparib in solution is not recommended; optimal stability is achieved at <-20°C as a solid (APExBIO).
• Olaparib is insoluble in ethanol and water; DMSO is required for experimental stock solutions (APExBIO).
• Not all DNA repair-deficient phenotypes confer Olaparib sensitivity; BRCAness or HRR gene loss is necessary (Borchert et al. 2019).
• Results from mouse xenograft models may not fully predict patient response due to interspecies differences.

Workflow Integration & Parameters

Olaparib (AZD2281, Ku-0059436) is supplied by APExBIO as SKU A4154 (product page). For in vitro experiments, a typical concentration is 10 μM applied for 1 hour in cell culture media. The compound is soluble at ≥21.72 mg/mL in DMSO, but insoluble in ethanol and water. For in vivo studies, Olaparib is administered intraperitoneally at 50 mg/kg/day for 14 days in mouse models. ATM kinase activity modulates sensitivity: ATM-deficient cells show heightened response. Stock solutions should be prepared in DMSO and stored below -20°C; avoid long-term solution storage to maintain compound integrity.

Conclusion & Outlook

Olaparib (AZD2281, Ku-0059436) is a validated, selective PARP-1/2 inhibitor for modeling homologous recombination deficiency, DNA damage response, and targeted therapy in BRCA-associated cancers. Its robust selectivity and reproducibility make it a standard in preclinical and mechanistic oncology research. Ongoing studies are expanding the utility of PARP inhibitors in combination therapies and beyond classical BRCA mutations, with gene expression profiling offering precision stratification (Borchert et al. 2019). APExBIO continues to provide high-quality reagents, such as Olaparib (SKU A4154), to empower translational and discovery research.